UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2020

HELIUS MEDICAL TECHNOLOGIES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Registrant’s Telephone Number, Including Area Code: (215) 944-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

---

 

Item 7.01 Regulation FD Disclosure.

 

On September 9, 2020, Helius Medical Technologies, Inc. (the “Company”) posted an updated corporate presentation to its website at http://heliusmedical.com/index.php/investor-relations/overview, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information set forth in this Item 7.01 and in the investor presentation attached hereto as Exhibit 99.1, is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.  The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

 

1

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

2

Exhibit 99.1 The Last Frontier in Healthcare Empowering the Natural Healing Process of the Brain September 2020

Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, whether the results of our clinical trials will be sufficient to  support an FDA, CE Mark or TGA approval of the PoNS™ device for marketing or whether the agencies may require that the Company conduct future clinical trials; future economic, competitive, reimbursement and  regulatory conditions; new product introductions; ability to commercialize its PoNS Treatment™; demographic trends; the intellectual property landscape; financial market conditions; continued availability of capital and  financing, including its ability to continue as a going concern; and future business and strategic decisions made by the Company and its competitors. These statements involve substantial known and unknown risks, uncertainties  and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may  not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ  materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Factors that may cause actual results to differ materially from any future results expressed or implied by any  forward looking statements include the impact of the COVID-19 pandemic, uncertainties associated with clinical trial enrollments and the results of clinical trials, uncertainties associated with the clinical development process and regulatory subimssion and approval process, and other risks described in the “Risk Factors” section of Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s Quarterly Report on Form 10-Q for the quarter ended June  30, 2020, as well as those set forth from time to time in the Company’s other filings with the securities and exchange commission and the Canadian securities regulators available at http://www.sec.gov or www.sedar.com The forward-looking statements in this presentation  represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking  statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our  views as of any date subsequent to the date of this presentation. Certain data in this presentation was obtained from various external sources. Neither the Company nor its affiliates, advisers or representatives have verified such data with independent sources. Accordingly, neither  the Company nor any of its affiliates, advisers or representatives make any representations as to the accuracy or completeness of that data or commits to update such data after the date of this presentation. Such  data involves risks and uncertainties and is subject to change based on various factors. The Company’s first product, known as the Portable Neuromodulation Stimulator (“PoNS"TM), is an authorized class II, non-implantable medical device authorized for sale in Canada. PoNS is intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy (“PoNS Treatment"TM). It is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”), and it is currently under review for clearance by the FDA for use in gait dysfunction due to MS and AUS Therapeutic Goods Administration. PoNS Treatment™ is not currently commercially available in the United States, the European Union or Australia. The Company has withdrawn its application from the EU marketing process due to uncertainty in Europe due to the switch from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) and the withdrawal of Lloyd’s Register Quality Assurance, the Company’s notified body, from the notified body business. The Company will reconsider submitting to the EU when conditions stabilize. www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Investment Highlights           Platform Technology Undervalued asset poised for growth:  science-backed neurotechnology with ready-to-scale operation        Large Lifetime             Addressable             Markets          PoNS Treatment™ First-in-Class, non-implantable neurotechnology with the opportunity to evolve with advancements in AI, compliance and data collection technologies Broad potential in treating symptoms of neurological disease, trauma, and potentially wellness and human performance High barrier to entry due to development timelines MS in Canada and US: ~1.2M  TBI in Canada and US: ~6.9M Other Neurological Disease/ Trauma CP Stroke Parkinson’s Cognitive and Human Performance Wellness Enhancement to the technology to further drive market adoption “Portable Neuromodulation Stimulator” with a controller & mouthpiece connected by a cord Electrodes on the mouthpiece send mild signals to the surface of the tongue exciting the neural network that flows to the brain Mild stimulation combined with physical therapy may enhance neuroplasticity

  Commercial www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Investment Highlights cont'd       Clinical Evidence           Regulatory Progress          Robust IP Portfolio FDA Breakthrough Device Designation; FDA submission for de novo classification and clearance related to MS pending Authorization for gait deficits due to mild and moderate symptoms of MS in Canada in March 2020 Authorization for balance deficit due to TBI in Canada in Oct 2018 TGA pending  ISO / MDSAP Certification Publications and real-world evidence showing improvements in gait or balance in MS Multiple publications showing statistically significant improvements in balance/gait in TBI Real world evidence appears to complement findings in RCTs Add’l studies in stroke, CP, to be developed Engagement of renowned KOLs and SAB Commercial infrastructure established Sales & Marketing success in Canada Research, Regulatory and Quality systems established Scale manufacturing and supply chain Reimbursement strategies in development for US China partners Exclusively licensed from inventors 29 US and 41 Foreign patents issued and owned by Helius Patents expire between 2026 and 2040 3 Chinese Design Patents Independent Verification of Patents and Freedom to operate

Dane Andreeff Interim CEO and Member, Board of Directors Dr. Jonathan Sackier Chief Medical Officer Joyce LaViscount Chief Financial Officer and Chief Operating Officer 17+ years in the medical devices industry Sales and Marketing Director, Boston Scientific Canada National Sales Manager, Canada Johnson & Johnson Former Media Relations and Marketing executive for Blue Jays & NHL Mark Leno VP, General Manager, Canadian Operations 30+ years in the health sciences industry Trained surgeon and pioneer of new medical technologies Has helped build several companies including medical technology, research and product- design and medical contract sales organizations 30+ years in the health sciences industry Accomplished pharmaceutical/healthcare public company CAO Former COO and CFO at MM Pharmaceutical Solutions Former Executive Director/Group Controller at Aptalis Pharmaceuticals Helius Leadership Team: Experienced Leadership With Healthcare and Commercialization Expertise 20+ years at Maple Leaf Partners as the General Partner and Portfolio manager, a value-based hedge fund which grew to over $2b in assets under management. Board member and trusted advisor to Helius Medical Technologies, Inc for over 3 years and HDL Therapeutics, Inc for over 15 years Owns approximately 3.4% of the company through Maple Leaf Partners and affiliates www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

Harry Kovelman, VP, Medical Affairs  Ellyn Ito, VP, Human Resources Larry Picciano VP, Quality & Regulatory Affairs 20+ years in clinical and research-oriented neurorehab physical therapy Neuromodulation research collaborator and Clinical Trial Manager at Univ Wisconsin  Former Director, PT and Clinical Study Manager at Wicab MS, Physical Therapy, University of Wisconsin Dr. Kim Skinner, DPT, PT Director, Physical Therapy 20+ years Human Resources in scale-ups, in tech, media & life-sciences in global public and private companies Former President & Managing Director, Sigma Integrated Resources Former CAO, Granahan McCourt Capital  Former, SVP, Human Resources, RCN Corp.,  Board Member, Redeemer Hospital Systems SPHR, HRCI 2005 20+ years global medical device quality and regulatory experience Extensive experience with electro-mechanical medical devices Former Quality, Regulatory and Clinical Head at Philips Former senior roles in Quality, Regulatory and Clinical Affairs at FujiFilm, Animas/J&J, CircuLite, Technidyne, St. Jude MBA, M.Eng.Sc, Penn State Helius Leadership Team: Deep Expertise in Key Functional Areas 25+ years medical affairs leader in rehabilitation, orthopedics and CNS  Proven experience in clinical operations, KOL and market development for innovative solutions Former Medical Director, Besins Critical Care, Convatec, Ferring, and Dynasplint Experience in practice management as former Executive Director of Orthopaedics at St. Joseph’s Medical  Lola Abhulimen Sr. Director, Clinical Operations 15+ years in Clinical Operations  Former Senior Trial Project Manager, Novocure Former, Clinical Operations Consultant at Quintiles, CRO and Consulting Services Former Clinical Trial Project Manager at United Global Health MBA, Penn State 13+ years in public accounting and SEC reporting with domestic and int'tl experience Former Director, SEC and Accounting Policy, Brightview Holdings Former Senior Audit Manager, Ernst & Young AB Former Sr. Accountant & SEC reporting, Exelon MS, Accountancy, Wake Forest Allison Northup, CPA Director, Accounting & Finance www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

Blane Walter Chairman of the Board, Member, Audit Committee, Nominating and Governance Committee Ed Straw Member, Compensation Committee, Nominating Committee Mitch Tyler Board Member Founder and Co-Inventor of PoNS™ technology Co-founder of Wicab, Inc and former VP, Research and Development Lead Inventor of the BrainPort Balance Device Former University of Wisconsin Biomedical Engineering faculty member MS, Biomedical Engineering and Registered Professional Engineer Jeff Mathiesen, CPA Chairman, Audit Committee Member, Compensation Committee Founder and Managing Partner of Osprey Venture Partners Chairman of Odyssey Logistics Member of the Board of Directors of Performance Equity Management, Capital Teas and Document Capture Technologies, Inc. Former President, Global Operations, Estee Lauder Former SVP, Global Manufacturing and Supply Chain Management at Compaq Computer Corporation Distinguished 3-star Admiral, US Navy Vice Chair, Lead Independent Director, and Audit Committee Chair of Sun Biopharma (Nasdaq: SNBP) Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation (OTCQB: NMTC) Former Board Member and Audit Committee Chair of eNeura, Inc. Former CFO at Teewinot Life Sciences Former CFO at Gemphire Therapeutics and Sunshine Heart  Partner, Talisman Capital Partners Vice Chair of InVentive Health Chair of the Governor of Ohio’s Executive Workforce Board Former CEO of InVentive Health Former Founder of InChord Communications www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Helius Board of Directors

Company Overview (as of June 30, 2020) Listed on the Nasdaq Capital Market since April 2018 (HSDT) - Market cap of $20M  Class A Common Stock shares issued and outstanding: 45.1M $5.3M Cash and no long-term debt as of June 30, 2020 China Medical Systems -  5.5% (ownership and development of PoNS asset in China )  Coverage by Steven Lichtman, Oppenheimer www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

Balance Maintenance in Baby Boomers (78M people) Neurological Wellness (1 billion people) Human Performance Stroke (7M People; 795K new each year) Cerebral Palsy (764K People) Indication and Target Population - US* Potential for Future Development Large Lifetime Addressable Market Additional Clinical Progress and Potential Opportunities Submitted to FDA for 510k de novo classification and clearance * See reference slides for sources DTC Driven Consumer Device Multiple Sclerosis (1M People) Pilot Studies Completed RCT Completed; additonal study planned. Traumatic Brain Injury (6.8M People) www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Parkinson’s Disease (1M People; 60K new each year) Future Studies Needed

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM 2020 - 2023 +$10bn 2021 - 2027 2025 - 2030 $1.5tn(2) Wellness / Betterment Preventative and Personalized Medicine Human Performance Improvement Cognitive Maintenance / Enhancement, Balance and Mobility, Neuro Recovery, Fall Prevention Medical Applications MS, TBI, Stroke, Cerebral Palsy Helius Target Market $10-15bn(1) 1 Grandview Research Brain Health Supplements Market Size, Industry Report, 2019-2025 2 Global Wellness Economy Monitor – October 2018 Large Lifetime Addressable Market Strategic Vision PoNS Lifecycle Management

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Smart Device The PoNS™ is a smart device that tracks frequency, duration and intensity of use PoNS Treatment ™ The PoNS™ Device  Data Intelligence Capabilities Data is uploaded to the cloud for analysis, the results of which provide compliance profiles for clinician review and payer reimbursement opportunities Treatment Hypothesis Researchers believe that targeted physical therapy performed during neurostimulation may promote neural network changes including rebuilding and reorganization (neuroplasticity) thereby restoring communication with the body and improving functionality such as balance Used in conjunction with physical therapy

~14MM pulses per 20-minute session Feels like champagne or carbonated water bubbles Trigeminal and Facial Cranial Nerve Branches25 Translingual Neurostimulation provides neuromodulation of the cranial nerves via the tongue Neuromodulation is the modification of nerve activity through delivery of a targeted stimulus PoNS Treatment™ Mechanism of Action www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Danilov Y et al. Cranial Nerve Noninvasive Neuromodulation: New Approach to Neurorehabilitation, in Kobeissy FH (ed): Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Frontiers in Neuroengineering. Boca Raton (FL), 2015. International Neuromodulation Society. January 24, 2013. Neuromodulation, or neuromodulatory effect. Available at https://www.neuromodulation.com/neuromodulation-defined. Accessed December 7, 2018.

Regulatory Progress FDA Submission under the Breakthrough Device Designation Published studies earned PoNS™ Breakthrough Device Designation for the treatment of gait deficits due to symptoms of Multiple Sclerosis  On August 4th, 2020, the Company filed its application to FDA for de novo classification and clearance of the PoNS™ Device for the treatment of gait deficit due to symptoms of Multiple Sclerosis FDA guides to a 150-day review period for 60% of de novo applications Our submission featured data from two published placebo controlled clinical trials and real-world evidence (RWE) from our treatment of people with MS in Canada  Data demonstrates acceptable risk benefit ratio We look forward to working interactively with FDA in the context of the Breakthrough Device Designation www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Regulatory Progress Evolution of Our Regulatory Strategy in Canada We received label expansion for MS by Health Canada on March 26, 2020    MS market characteristics 93,500 MS patients in Canada Strong advocacy for MS (MS Society) Urgency to treat Similar treatment protocol as mmTBI Brain Injury Canada. Acquired Brain Injury (ABI) – The Basics. Available at https://www.braininjurycanada.ca/acquired-brain-injury/. Accessed February 26, 2020. Brain Injury Association of Durham Region. About Brain Injury. Available at https://biad.ca/about-brain-injury/. Accessed February 28, 2020. Li, M., Zhao Z., Yu G., Zhang, J. Epidemiology of traumatic brain injury over the world: a systematic review. Austin Neurology & Neurosciences. 2016;1(2):1007 Kleffelgaard I et al. Disabil Rehabil. 2012;34(9):788-794. https://www.cihi.ca/en/canadian-multiple-sclerosis-monitoring-system-metadata TBI Authorization in October 2018 Mild to Moderate TBI market characteristics ~350,000 patients in Canada Build collaborative network with Payors Developing key KOLs in TBI treatment

Study entry 2 wks lab 4 wks home 8 wks home 12 wks home Weeks DGI* Change *p < 0.05 **p < 0.01 *** p < 0.005 Clinically significant Two groups (10 each): “Active” PoNS + exercises Placebo PoNS + exercises Clinical Evidence Multiple Sclerosis Study – Mild and Moderate MS (EDSS score 3.5-6) Tyler et al. Journal of NeuroEngineering and Rehabilitation 2014, 11:79 All 10 subjects in the active treatment group experienced at least a 4 point improvement from baseline to Week 14 in DGI.   Mean average of 7.95. Only 3 of 10 (30%) subjects in the placebo control group experienced an improvement in DGI of at least 4 points from baseline to week 14.  Mean average of 3.45.  Mean DGI* 10 Active 10 Control *DGI = Dynamic Gait Index, a measure of the ability to walk www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM 100% Improvement in Dynamic Gait Index scores for the Active Group

Clinical Evidence Real-World Evidence in MS Patients Treated with PoNS™ in Canada 42 patients with MS were treated with PoNS in Canada between March 2019 and September 2019 in a validated electronic database capture system and Participant Disposition, Demographics, and Clinical Characteristics reflect improvements similar to other studies reported in literature evaluating physical therapy outcomes. www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM 58.3% Patients had an overall average* improvement in their functional gait assessment  (FGA) *An average improvement in FGA surpasses the MDC for older adults, stroke patients and those with Parkinson's disease Helius Medical Technologies. Data on File.

Clinical Evidence TBI-001: SOT Responders at 5 Weeks in Pooled and HFP Population While the trial included both high and low frequency groups, there was no statistical difference between patients between groups so the data was pooled.  67.2 0 20 40 60 80 100 Pooled SOT responders,a % HFP = high-frequency pulse; LFP = low-frequency pulse; SOT = Sensory Organization Test. aResponders were defined as participants who had an improvement of ≥ 15 points in SOT score from baseline. Helius Medical Technologies. Data on File. 023_Appendix 18. Helius Medical Technologies. Data on File P = 0.0005 57.4% Who were in the normal range for balance at end of the study(2) 71.2% Were Responders (i.e., 15 point SOT score improvement) HFP(1) Trial Outcomes www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

In patients with mmTBI, balance improvements shown at 2 Weeks, 14 Weeks and 26 Weeks 0 10 20 30 40 50 60 70 80 90 SOT Baseline Week 26 ∆ 29.8 ∆ 21.0 ∆ 33.8 Normal Range SOT Score Week 14 N=221 12-week washout period – no stimulation On average, patients with mmTBI improved from an impaired SOT score to normal SOT score in 14 weeks of treatment with HFP version of PoNS™ device On average, normal SOT  score was maintained  throughout the 12-week  washout period for all  patients Week 2 HFP+PT Clinical Support for PoNS Treatment™: Long-term Treatment Study in mild-to-moderate TBI  Long-term Treatment Study in mmTBI Sensory Organization Test (SOT) Score Comparison 1 Patients treated with high frequency pulse (HFP) device. Low frequency pulse (LFP) data not shown since it was not statistically different from HFP. Archives of Rehabilitation Research and Clinical Translation (2019), doi: https://doi.org/10.1016/j.arrct.2019.100026. www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM 350,000 patients in Canada 19 Clinic Locations Target of 25 at end of 2020 Engagement w/ Toronto Rehabilitation Mild-to-Moderate Traumatic Brain Injury (“mmTBI”) 93,500 patients in Canada High urgency to treat High Patient Awareness Specialty clinic system Engagement with MS Society of Canada Multiple Sclerosis (“MS”) Helius’ target markets in Canada are providing meaningful real-world clinical experience Commercialization Canadian Market Opportunity Brain Injury Canada. Acquired Brain Injury (ABI) – The Basics. Available at https://www.braininjurycanada.ca/acquired-brain-injury/. Accessed February 26, 2020. Brain Injury Association of Durham Region. About Brain Injury. Available at https://biad.ca/about-brain-injury/. Accessed February 28, 2020. Li, M., Zhao Z., Yu G., Zhang, J. Epidemiology of traumatic brain injury over the world: a systematic review. Austin Neurology & Neurosciences. 2016;1(2):1007 Kleffelgaard I et al. Disabil Rehabil. 2012;34(9):788-794. https://www.cihi.ca/en/canadian-multiple-sclerosis-monitoring-system-metadata

Establish robust network of Canadian Clinics to deploy PoNS 19 established clinic locations to date Additional 6 clinics to target 25 by year-end New neuro-centric clinics in Ontario, Western Canada & Quebec Label expansion for MS approved in March 2020 Gain KOL support through clinical experience programs (CEP) in Canada’s most respected Neuro Treatment Centers Partnership with Toronto Rehab for TBI Partnership with MS Society of Canada for MS Drive reimbursement by using health economic data to establish financial ROI for treatment Engaging, training and authorizing Canadian clinics to provide PoNS Treatment™ Commercialization Canadian Strategic Focus www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

AUSTRALIA: Awaiting decision from Therapeutic Goods Administration (TGA) Submission review in process – we supplemented our submission and responded to all follow-up questions to date EU: Company withdrew its CE Mark Application Decision made due to EU’s move to Medical Device Regulation (MDR) from Medical  Device Directive (MDD), and the Company’s Notified Body (LRQA) withdrawal from the business created uncertainty in clearance process New notified body in place – GMED; Company will resubmit once EU process clarity returns CHINA: October 2015, Strategic Agreement with A&B, LTD (later transferred to China Medical Systems or  "CMS")  for development and commercialization of PoNS in China plus 4 territories;  Transferred ownership of Asian patents, patent applications and granted exclusive license to market, promote distribute and sell the technology Assumed all development, patent (both application and defense), future manufacturing, clinical trial, and regulatory clearance costs for the Territories International Strategy www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM Extensive IP Portfolio A Significant Barrier to Competitor Entry Exclusively licensed from inventors (4% royalty): 9 US Medical Method Patents Issued Patents expire between 2029 and 2031 Patents owned by Helius (no royalty): 29 US Patents Issued 41 Foreign Patents Issued Patents expire between 2026 and 2040 Helius Patents Transferred to China Medical System Holdings (CMS): 3 Chinese Design Patents Independent Verification of Patents and Freedom to Operate Opinion September 2017

THANK YOU www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM

References Slide 9: Disease State Prevalence MS https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s Cerebral Palsy: http://www.cerebralpalsy.org/about-cerebral-palsy/prevalence-and-incidence Stroke – http://www.strokeassociation.org/STROKEORG/LifeAfterStroke/Life-After-Stroke_UCM_308546_SubHomePage.jsp–https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_stroke.htm Grandview Research Brain Health Supplements Market Size, Industry Report, 2019-2025 Global Wellness Economy Monitor – October 2018 Parkinson’s Disease https://www.parkinson.org/Understanding-Parkinsons/Statistics#:~:text=Approximately%2060%2C000%20Americans%20are%20diagnosed,are%20diagnosed%20before%20age%2050. www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM